Drueckes Peter
CPC Screening Sciences, Novartis Pharma AG, Novartis Institutes for Biomedical Research, 4002, Basel, Switzerland.
Methods Mol Biol. 2016;1439:143-57. doi: 10.1007/978-1-4939-3673-1_9.
Biochemical selectivity profiling is an integral part of early drug development. Typically compounds from optimization phase are regularly tested for off-target activities within or across target families. This article presents workflow and critical aspects of biochemical protein kinase profiling based on microfluidic mobility shift assays.
生化选择性分析是早期药物开发不可或缺的一部分。通常,处于优化阶段的化合物会定期针对目标家族内部或跨目标家族的脱靶活性进行测试。本文介绍了基于微流控迁移率变动分析的生化蛋白激酶分析的工作流程和关键方面。